Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acculax is a combination laxative formulation marketed by Emblazon Life Sciences, primarily indicated for the symptomatic relief of constipation. It utilizes a multi-modal approach by combining three active ingredients: sodium picosulfate, liquid paraffin, and magnesium hydroxide (milk of magnesia). Sodium picosulfate is a stimulant laxative that undergoes bacterial hydrolysis in the colon to form an active metabolite that stimulates the enteric nervous system, thereby increasing intestinal peristalsis. Liquid paraffin serves as a lubricant laxative, coating the fecal mass and the intestinal wall to reduce water absorption and facilitate smoother passage of stool. Magnesium hydroxide acts as an osmotic laxative, drawing water into the intestinal lumen through an osmotic gradient, which increases stool volume and softens consistency. This combination is typically administered as an oral suspension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sodium Picosulfate + Liquid Paraffin + Magnesium Hydroxide.